Transforming Growth Factor Beta/Smad Signaling: A Therapeutic Target of Chinese Herbal Medicine for Kidney Disease.
文献摘要
Transforming growth factor beta/Smad signaling has emerged as a promising therapeutic target for kidney disease. Increasing evidence suggests that Chinese herbal medicine (CHM), including single herbs, bioactive compounds, herb pairs, and multi-herb formulas, modulates this signaling network in acute kidney injury, chronic kidney disease, and transitions of acute kidney injury-to-chronic kidney disease and acute kidney injury-on-chronic kidney disease. Frequently studied herbs include Rheum officinale (rhubarb), Wolfiporia cocos (Fu Ling), Scutellaria baicalensis (HuangQin), Salvia miltiorrhiza (Dan Shen), Astragalus membranaceus (Huang Qi), and Coptis chinensis (Huang Lian). Experimental studies suggest that CHM interventions act at multiple regulatory levels, including Smad3 activation, Smad3/Smad7 balance, post-translational modification, and epigenetic regulation, while also interacting with oxidative stress, ferroptosis, inflammatory signaling, microRNA regulation, gut microbiota, and renal-immune cell crosstalk. Overall, CHM shows promise as a multitarget strategy against transforming growth factor beta 1/Smad-driven kidney fibrosis, but further mechanistic and multicenter clinical trials are needed.